Ferric derisomaltose
Monoferric (ferric derisomaltose) is an oligosaccharide pharmaceutical. Ferric derisomaltose was first approved as Monoferric on 2020-01-16. It is used to treat iron-deficiency anemia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Monoferric (discontinued: Monoferric)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ferric derisomaltose
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MONOFERRIC | Pharmacosmos | N-208171 RX | 2020-01-16 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| monoferric | New Drug Application | 2024-09-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| iron-deficiency anemia | — | D018798 | D50 |
Agency Specific
FDA
EMA
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J1437 | Injection, ferric derisomaltose, 10 mg |
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Iron deficiencies | D000090463 | — | E61.1 | 1 | 1 | 13 | 8 | 4 | 27 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | 13 | 8 | 4 | 26 |
| Iron-deficiency anemia | D018798 | — | D50 | — | 1 | 12 | 8 | 3 | 24 |
| Deficiency diseases | D003677 | EFO_1001067 | E63 | — | 1 | 6 | 1 | 1 | 9 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | 5 | 1 | 7 |
| Left ventricular dysfunction | D018487 | — | — | — | — | — | 1 | — | 1 |
| Birth weight | D001724 | EFO_0004344 | — | — | — | — | 1 | — | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | 1 | — | 1 |
| Spinal dysraphism | D016135 | EFO_1001210 | Q05 | — | — | — | 1 | — | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypophosphatemia | D017674 | HP_0002148 | — | — | — | 2 | — | — | 2 |
| Female genital neoplasms | D005833 | — | — | — | — | 2 | — | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | — | — | 1 |
| Uterine hemorrhage | D014592 | — | — | — | — | 1 | — | — | 1 |
| Emergencies | D004630 | — | — | — | — | 1 | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
| Peritoneal dialysis | D010530 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiac surgical procedures | D006348 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obstetric labor complications | D007744 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neurodevelopmental disorders | D065886 | — | F89 | — | — | — | — | 2 | 2 |
| Fetal diseases | D005315 | — | — | — | — | — | — | 1 | 1 |
| Child development | D002657 | — | — | — | — | — | — | 1 | 1 |
| Autism spectrum disorder | D000067877 | — | F84.0 | — | — | — | — | 1 | 1 |
| Replacement arthroplasty knee | D019645 | — | — | — | — | — | — | 1 | 1 |
| Methemoglobinemia | D008708 | — | D74 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ferric derisomaltose |
| INN | ferric derisomaltose |
| Description | Ferric derisomaltose (FDI), sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). It was approved for use in the United States in January 2020. It is given intravenously.
|
| Classification | Oligosaccharide |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1345510-43-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298187 |
| ChEBI ID | — |
| PubChem CID | 86278348 |
| DrugBank | DB15617 |
| UNII ID | AHU547PI9H (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 662 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
912 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use